York Bioanalytical Solutions
York Bioanalytical Solutions is recorded as a service provider in 34 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 34 trials · Latest update first
A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin Versus Sapropterin in Participants With Phenylketonuria ≥2 Years of Age
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Of 82 enrolled participants tested for sepiapterin responsiveness in Part 1, 62 were randomized for Part 2; 15 were nonresponders and 5 did not meet Part 1 eligibility criteria.
- Protocol amendments modified eligibility criteria, ultimately specifying exclusion of incapacitated adults, and clarified the primary analysis set and efficacy-endpoint analyses.
- Protocol amendments clarified Part 1 and Part 2 washout periods, dietary-control observation duration, and added a +1-day window for virtual visits.
- Enrollment of participants with biochemically diagnosed classical PKU was capped at 30% of the safety analysis set.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements
Sponsor Charm Therapeutics Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
C5091018 - An Interventional Efficacy And Safety, Phase 3, Randomized, Double-Blind, 3-Arm Study To Investigate Ibuzatrelvir in Adults With Symptomatic COVID-19 Who Are Severely Immunocompromised
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies.
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study randomized 378 patients at 58 sites in 14 countries.
- Tebentafusp required at least 16 hours of inpatient monitoring after dosing on Cycle 1 Days 1, 8, and 15 because of anticipated cytokine release syndrome.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase 2 Study of Zelenectide Pevedotin in Participants with NECTIN4 Amplified Advanced Breast Cancer
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
C4671026-A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID-19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism
Sponsor Zealand Pharma A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, parallel group, multi-center study to evaluate the long-term safety of salbutamol rescue medication when administered via metered dose inhalers containing the propellant HFA-152a or reference HFA-134a.
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Doubleblind, Randomized, Placebocontrolled Study (MCT8-2021-3 (ReTRIACt))
Sponsor Rare Thyroid Therapeutics International AB
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for York Bioanalytical Solutions?
The 2026-10-09 snapshot links York Bioanalytical Solutions to 34 distinct CTIS trials. Recorded services include Laboratory services, Biomarker Development and Bioanalysis, Payment services, Pharmacokinetics, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for York Bioanalytical Solutions?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Gynecology, Neurology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to York Bioanalytical Solutions conducted?
The linked trials record locations in 24 countries, including Spain, France, Poland, Germany, Italy. These are trial locations, not confirmed office locations or countries where York Bioanalytical Solutions delivered services.
What can this page tell me about York Bioanalytical Solutions's trial experience?
Browse 34 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under York Bioanalytical Solutions. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- York Bioanalytical Solutions Limited